Exit & PE Decisions
Should I Sell My Veterinary Practice to a PE Group or Keep Running It?
There is no single right answer, but there is a right way to make the decision: model both paths with your real numbers before a broker or a consolidator's business-development rep ever calls. Selling converts years of built equity into cash today, a shorter leash, and a buyer's timeline; staying independent keeps full control and the upside of a still-consolidating market, at the cost of carrying every risk yourself. Corporate consolidators now own 22% of all veterinary businesses, up from 16% just three years ago, so this decision is arriving faster for more owners than it used to. Below is what a PE deal actually pays, what you actually keep, what changes about your role, and how to know whether now is the right time to decide at all.
Updated
Should I sell my veterinary practice to a PE group or keep running it?
It depends on what you are actually optimizing for: certainty and liquidity now, or control and unrealized upside later. A PE sale converts a large, illiquid asset (your practice) into a mix of cash and a multi-year commitment to someone else's scorecard. Staying independent keeps the freedom to run the practice your way and the chance to sell later at a higher multiple as you grow, but it also means you alone absorb every recruiting shortfall, rate hike, and slow quarter between now and whenever you do sell.
- Corporate consolidators now own 22% of all veterinary businesses, up from 16% just three years earlier, and sole proprietorships have fallen to 9% of the market.(2026 AVMA Economic Report, via Petconomist)
Takeaway: This is a tradeoff between certainty and upside, not a math problem with one correct answer; the numbers just tell you what each path is actually worth.
Top Practice CFO models both paths side by side against your real ledger, so the decision is based on your numbers, not a generic industry rule.
What is my veterinary practice actually worth to a PE buyer right now?
Independent-sized practices commonly land in the 3x to 5x adjusted-EBITDA range, while practices attractive to a consolidator, generally multi-doctor with a higher earnings base, can command 6x to 12x or more depending on size and growth. A mid-size, multi-doctor general practice doing $2.5M to $4.5M in revenue with $400K to $800K of EBITDA typically sees offers in the high single digits; a scaled multi-site or specialty practice over $7M in revenue can see low-double-digit multiples and higher. The exact number moves with doctor count, growth trend, and how clean your earnings are, which is why two practices with similar revenue can price very differently.
- A multi-doctor general practice doing $2.5M-$4.5M in revenue ($400K-$800K EBITDA) has seen direct-offer multiples of 5.5x to 7.5x EBITDA, while a scaled multi-site or specialty/ER practice over $7M in revenue has seen direct offers of 9x to 12x.(TransitionsElite)
- A 2025-26 private-markets valuation survey assigns veterinary practices a typical range of 8x to 14x EV/EBITDA, and industry advisory iVET360 notes high-performing practices typically transact at 8x to 13x.(QuantPillar, via TransitionsElite)
| Practice profile | Revenue / EBITDA | Typical direct-offer multiple |
|---|---|---|
| Multi-doctor GP, regional | $2.5M-$4.5M rev / $400K-$800K EBITDA | 5.5x-7.5x |
| Multi-doctor, sustained growth | $4.5M-$7M rev / $800K-$1.4M EBITDA | 7x-9x |
| Scaled multi-site or specialty/ER | $7M+ rev / $1.4M+ EBITDA | 9x-12x |
Takeaway: The headline multiple is a starting point, not a quote; it is set by your size, growth trend, and how normalized your earnings already are.
Top Practice CFO's 14-Day Financial X-ray calculates your normalized EBITDA and tells you, in writing, which multiple band your practice realistically sits in today.
What's the real difference between a direct offer and running a competitive sale process?
A direct offer is the number one buyer proposes when they approach you first, and it is priced to be good enough that you never shop it around. A competitive process, run by an advisor who markets the practice to multiple consolidators at once, routinely produces a meaningfully higher multiple because buyers are now bidding against each other instead of against your inertia. The gap is not small: on a practice with $1 million in normalized EBITDA, the difference between a 6x direct offer and an 11x competitive close is $5 million.
- On a practice doing $1 million in normalized EBITDA, the difference between a 6x direct offer and an 11x competitive close is $5 million.(TransitionsElite)
- The same $2.5M-$4.5M-revenue practice profile that sees 5.5x-7.5x on a direct offer has seen 9x-12x through a competitive process; a $7M+ scaled or specialty practice has seen 13x or higher competitively versus 9x-12x direct.(TransitionsElite)
Takeaway: Never treat the first offer you get as the market price for your practice; it is one buyer's opening number, not a competitive result.
Top Practice CFO gets your financials competitive-process-ready, normalized and defensible, before you ever take the first call from a consolidator's BD team.
How much of a PE deal is actually cash I get to keep at closing?
The headline multiple is not the check you cash. A typical PE offer breaks into four pieces: cash at closing, an earnout tied to future performance, rollover equity in the buyer's platform, and sometimes a small seller note. Cash at close commonly runs 60% to 80% of total deal value; the rest is earned over time, tied to metrics, or locked up until the platform itself eventually sells.
- Cash at closing typically runs 60% to 80% of total deal value; earnouts run 1 to 3 years (2 years is common) and represent 10% to 25% of total deal value, tied to revenue, gross profit, or EBITDA; rollover equity commonly runs 10% to 30% of deal value and stays illiquid until the platform's own eventual exit, typically 3 to 7 years out.(Dechert LLP / Holland & Knight, via TransitionsElite)
| Component | Amount | Share of deal | When you actually get it |
|---|---|---|---|
| Cash at close | $8.4M | 70% | At closing |
| Earnout | $1.8M | 15% | Over up to 3 years, tied to performance |
| Rollover equity | $1.5M | 12.5% | Illiquid until the platform exits, 3-7 years |
| Seller note | $300K | 2.5% | Paid over several years |
Takeaway: Ask what the deal is worth in cash at close, not just what multiple is on the term sheet; those are two different numbers.
Top Practice CFO models the actual after-tax, time-weighted cash from any offer structure before you sign a letter of intent, so you know what you are really being paid.
What happens to my role and my team after I sell to a PE group?
Most sellers do not walk away at closing. Because a meaningful share of the deal is earnout tied to continued performance, you typically stay on as a clinician or medical director under a multi-year employment or clinical-services agreement, and you sign a non-compete that limits where you can practice if you ever leave. Your team generally keeps their jobs in the near term, since staff and associate-DVM continuity is usually one of the things the earnout is measured against, but they now report into a corporate structure with standardized scorecards instead of your judgment call.
- The standard non-compete length in veterinary medicine is one to two years; the typical geographic radius runs three to five miles for a general-practice DVM and around fifteen miles for a specialist.(Aurora Search Consultants)
Takeaway: Read the employment and non-compete terms as closely as the price; the earnout does not pay out until you have actually worked the years it's tied to.
Top Practice CFO models each realistic earnout scenario in expected-value terms, not just the best case printed on the term sheet, before you sign.
What are the real risks of selling to a PE group?
The biggest risk is not the price, it's the years afterward. You trade decision-making authority for a corporate reporting structure, and a meaningful piece of your payout (the rollover equity) is illiquid for years and only worth what the platform is worth when it eventually exits, which is genuinely uncertain. If the cultural fit with the new ownership is bad, you are still bound by an earnout you need to hit and a non-compete that limits your options if you decide to leave early.
- Rollover equity commonly represents 10% to 30% of total deal value and stays illiquid until the acquiring platform's own eventual exit, typically 3 to 7 years after your closing.(Dechert LLP / Holland & Knight, via TransitionsElite)
Takeaway: Treat rollover equity as a real bet on the platform's future value, not as cash you have already banked.
Top Practice CFO quantifies what your rollover equity would actually need to be worth to beat simply taking more cash at close, so the decision isn't a leap of faith.
What are the real costs of staying independent instead of selling?
Staying independent means competing for doctors and staff against corporate comp packages, funding growth and equipment out of your own cash flow instead of a platform's capital, and, in specialty and emergency care especially, relying on referral relationships that a competitor may now own outright. The consolidation trend is not slowing down, and every year an independent practice waits, more of the local competitive and referral landscape shifts toward corporately owned groups.
- Corporate groups now control roughly 75% to 80% of all specialty and emergency pet hospitals in the U.S.(2026 AVMA Economic Report, via Petconomist)
| Ownership type | 3 years ago | 2026 |
|---|---|---|
| Corporate consolidator owned | 16% | 22% |
| Sole proprietorship | higher than today | 9% |
Takeaway: Staying independent is a legitimate choice, but it is an active one; it works only if the practice keeps getting more competitive, not just older.
Top Practice CFO builds the plan that keeps an independent practice bankable and competitive on its own, without needing a PE partner to fund growth.
How do I know if now is the right time to decide, or if I should wait a few years?
Waiting only helps if the practice is genuinely improving: normalized EBITDA growing, doctor and staff retention stable, and the books clean enough to survive real due diligence. Waiting does not help if the practice is simply aging in place, because a static or shrinking earnings base does not move you into a higher multiple band, it just delays the same decision at the same or a worse price. Before setting a timeline, get an honest read on which multiple band your practice would realistically sit in today, direct-offer or competitive-process, and what specifically would move it up a band.
- A 2025-26 private-markets survey puts the typical veterinary practice valuation range at 8x to 14x EV/EBITDA, with high performers transacting at 8x to 13x, so growth and earnings quality, not just the calendar, are what move a practice up that range.(QuantPillar / iVET360, via TransitionsElite)
Takeaway: Only wait if you can name the specific number (EBITDA, doctor count, retention) that gets better while you do; otherwise waiting is just delay.
Top Practice CFO's 14-Day Financial X-ray gives you that honest read on where your practice sits today, in writing, before you commit to either timeline.
How does a fractional CFO help me decide between selling and staying independent?
A fractional CFO normalizes your EBITDA, the single number the entire conversation runs on, and then models both paths side by side: after-tax, time-weighted proceeds from a realistic sale structure versus continued distributions and compounding practice value if you stay independent. That same normalization work also raises your multiple and your credibility with a buyer whichever path you choose, so it is not wasted if you end up staying. It is senior CFO judgment sized to a practice your size, not a full-time hire you do not need for a decision you make once.
- A fractional CFO retainer commonly runs $2,500 to $9,500 a month, against a full-time CFO's total compensation of roughly $180,000 to $250,000 a year.(OpsFi 2026)
Takeaway: The financial work that prepares you to sell well and the financial work that makes staying independent worth it are the same work; do it before you decide, not after.
Top Practice CFO's 14-Day Financial X-ray models both the sale scenario and the stay-independent scenario against your real ledger, in writing, so the decision is yours to make with real numbers.
Frequently asked questions
- Should I sell my veterinary practice to a PE group or keep running it?
- It depends on whether you value certainty and cash now more than control and upside later. Model both paths against your real, normalized EBITDA before deciding; a sale converts built equity into cash and a multi-year commitment, while staying independent keeps control but means carrying every risk yourself.
- How much is my veterinary practice worth to a PE buyer?
- Independent-sized practices commonly see 3x to 5x adjusted EBITDA; practices attractive to a consolidator, generally multi-doctor with a larger earnings base, can see 6x to 12x or higher. The exact multiple depends on size, growth, and how normalized your earnings are, and can differ by several points between a direct offer and a competitive sale process.
- How much of a PE deal is cash versus earnout versus rollover equity?
- Cash at closing typically runs 60% to 80% of total deal value. Earnouts, tied to performance over 1 to 3 years, commonly represent 10% to 25% of the deal. Rollover equity, usually 10% to 30% of the deal, stays illiquid until the buyer's platform eventually exits, often 3 to 7 years later.
- Do I have to keep working after I sell my veterinary practice to PE?
- Almost always, yes, at least for a period tied to your earnout, typically under a multi-year employment or clinical-services agreement. You will also generally sign a non-compete, commonly one to two years and a three-to-five-mile radius for a general-practice DVM, longer for specialists.
- What percentage of veterinary practices are now corporate owned?
- Corporate consolidators own 22% of all veterinary businesses as of the 2026 AVMA Economic Report, up from 16% three years earlier, and control 75% to 80% of specialty and emergency hospitals specifically. Sole proprietorships have fallen to 9% of the market.
- Is it better to sell my veterinary practice now or wait a few years?
- Waiting only helps if normalized EBITDA, doctor retention, and the cleanliness of your books are genuinely improving, since those are what move a practice into a higher multiple band. A practice that is simply aging in place, without those numbers improving, does not get more valuable by waiting.